Search This Blog

Friday, December 20, 2019

J&J acquires Taris Biomedical

Johnson & Johnson (NYSE:JNJ) acquires privately held TARIS Biomedical LLC for an undisclosed sum.
The Lexington, MA-based biotech is developing a novel technology (TARIS System) enabling the continuous local delivery of therapies for bladder diseases. Lead candidate is TAR-200 for muscle invasive bladder cancer.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)